Furthermore, using ICI monotherapy in patients with EGFR mutant NSCLC who failed to respond to EGFR‐TKIs and without acquired T790M mutation is not recommended in the clinical practice guidelines of the European Society for Medical Oncology (ESMO).29 Here, EGFR is linked to non-small cell lung carcinoma.